Advertisement

Training Programs for Cytoreductive Surgery and HIPEC

  • Beate Rau
  • Maria Clara Arroyave
  • Dusan Klos
Chapter

Abstract

Peritoneal surface malignancy (PSM) is associated with poor prognosis. Mean overall survival is 6 months. Historically, patients diagnosed with peritoneal metastasis derived from a solid tumour such as colorectal cancer, appendiceal cancer, ovarian cancer, gastric cancer, gynaecological malignancies or peritoneal mesothelioma receive only chemotherapy with palliative intention, because distant metastases especially PSM are associated with poor prognosis.

References

  1. 1.
    Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995;221(1):29–42.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Sugarbaker PH, Cunliffe WJ, Belliveau J, de Bruijn EA, Graves T, Mullins RE, Schlag P. Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer. Semin Oncol. 1989;16:83–97.PubMedGoogle Scholar
  3. 3.
    Sugarbaker PH. Parietal peritonectomy. Ann Surg Oncol. 2012;19(4):1250–2229.CrossRefPubMedGoogle Scholar
  4. 4.
    Baratti D, Kusamura S, Cabras AD, Deraco M. Cytoreductive surgery with selective versus complete parietal peritonectomy followed by hyperthermic intraperitoneal chemotherapy in patients with diffuse malignant peritoneal mesothelioma: a controlled study. Ann Surg Oncol. 2012;19(5):1416–24.CrossRefPubMedGoogle Scholar
  5. 5.
    Baratti D, Kusamura S, Iusco D, Bonomi S, Grassi A, Virzi S, Leo E, Deraco M. Postoperative complications after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy affect long-term outcome of patients with peritoneal metastases from colorectal cancer: a two-center study of 101 patients. Dis Colon Rectum. 2014;57(7):858–68.CrossRefPubMedGoogle Scholar
  6. 6.
    Piso P, Leebmann H, Marz L, Mayr M. Cytoreductive surgery for malignant peritoneal tumors. Chirurg. 2015;86(1):38–46.CrossRefPubMedGoogle Scholar
  7. 7.
    Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De SM, Barone R, Yonemura Y, Cavaliere F, Quenet F, Gutman M, Tentes AA, Lorimier G, Bernard JL, Bereder JM, Porcheron J, Gomez-Portilla A, Shen P, Deraco M, Rat P. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22(16):3284–92.CrossRefPubMedGoogle Scholar
  8. 8.
    Kusamura S, Moran BJ, Sugarbaker PH, Levine EA, Elias D, Baratti D, Morris DL, Sardi A, Glehen O, Deraco M. Multicentre study of the learning curve and surgical performance of cytoreductive surgery with intraperitoneal chemotherapy for pseudomyxoma peritonei. Br J Surg. 2014;101(13):1758–65.CrossRefPubMedGoogle Scholar
  9. 9.
    Koppe MJ. Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg. 2006;243.Google Scholar
  10. 10.
    Weir HK. Annual report to the nation on the status of cancer, 1975–2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst. 1995.Google Scholar
  11. 11.
    Virzi S. Hyperthermic Intraperitoneal Chemotherapy (HIPEC) techniques. Treatment of peritoneal surface malignancies. Milan: Springer-Verlag Italia; 2015.Google Scholar
  12. 12.
    Kusamura S. Learning curve for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal surface malignancies: analysis of two centres. J Surg Oncol. 2012;107.Google Scholar
  13. 13.
    Bagnoli PF, et al. Peritonectomy and hyperthermic intraperitoneal chemotherapy: cost analysis and sustainability. Eur J Surg Oncol. 1943.Google Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  1. 1.Special Surgical OncologyCharité – University of BerlinBerlinGermany
  2. 2.Surgical Oncology DepartmentClinica SomerRionegroColombia
  3. 3.1st Department of SurgeryUniversity Hospital OlomoucOlomoucCzech Republic

Personalised recommendations